Although compassionate use is possible, it is more important that, either, or a combination, of these two routes of administration in a randomized, pilot trial be used to properly assess the possibility that the innate immune system stimulant, GM-CSF, may reduce morbidity and mortality from COVID-19, as the studies discussed above suggest. Here, CSF2 is linked to COVID-19.